Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's Board of Directors

Algeta ASA : Hilde Furberg and Paolo Pucci elected as new members of Algeta's 
Board of Directors 
OSLO, NORWAY -- (Marketwired) -- 04/12/13 --  Algeta ASA (OSE:
ALGETA), a company focused on the
development of novel targeted
cancer therapeutics, is very pleased  to announce
that Mrs Hilde
Furberg and Mr Paolo Pucci were elected as new Non-executive members
of its Board of Directors at the Company's annual general meeting
in Oslo on 11 April 2013. 
Hilde  Furberg  (born  1958) has  30 years  of  experience in the
industry.  She is currently  Senior Vice President 
Rare Disease EMEA at Genzyme
(Sanofi),  which she joined in 2002. She
 opened the first operation for Genzyme
in  the Nordic region and has
also  had management responsibility for Genzyme in the  BeneLux
region. Prior to  Genzyme, Mrs Furberg spent  15 years at Baxter in
various  business roles of increasing seniority. She is a
Non-executive Director
on  the Board of Clavis Pharma ASA and is a
board member of Copenhagen Capacity.
Previous board memberships
include Probi AB and Pronova Biopharma ASA (until the acquisition by
Mrs  Furberg holds  a Master  of Science  degree in Nuclear
Analytical Chemistry
from  the  University  of  Oslo.  She  is  a
Norwegian citizen and resides in de Naarden, Netherlands. 
Mrs Furberg holds 200 shares and no options in Algeta ASA and she has
not worked
as a consultant for the Company. 
Paolo  Pucci (born 1961) is Chief  Executive Officer and member  of
the Board of Directors of ArQule Inc., a US-based, Nasdaq-listed
cancer therapeutics company,
which  he joined in 2008. Before  this,
Mr Pucci was  at Bayer AG, where he held
responsibilities  as  Country  Head  Bayer  Italy
President   &  SVP  Bayer  Pharmaceuticals  North 
America  -  Global Specialty
Pharmaceuticals, and member of the Bayer
Pharmaceuticals Executive Committee. He concluded  his  tenure  at 
Bayer  as  President in charge of the Bayer- Schering
 Global Oncology/Specialized Therapeutics Business Units and was
instrumental in building Bayer's global oncology franchise for
Nexavar((R)). Prior to  this, Mr  Pucci held  positions of 
increasing responsibility with Eli Lilly
between  1992 and 2001,
culminating  with his  appointment as Managing Director,
Eli  Lilly
Sweden AB. Mr  Pucci is Non-executive Director  on the Board of
Mr  Pucci holds an MBA from  the University of Chicago and  is a
graduate of the Universita  Degli  Studi  Di  Napoli  in  Naples, 
Italy. Mr Pucci is an Italian
citizen and resides in Boston, MA, USA. 
Mr Pucci holds no shares and no options in Algeta ASA and he has not
worked as a consultant for the Company. 
Stein  Holst Annexstad, Algeta's Chairman, said: "We are very pleased
to welcome
Hilde  and  Paolo  to  the  Algeta  Board.  Between  them,
they have a wealth of experience  in the global  pharma industry and 
particularly in the clinical and commercial  development of
innovative targeted cancer therapies. We look forward
to  the 
valuable  contributions  they  will  make  to  the  further growth
and development of Algeta. We would also like to thank Ingrid Wiik and
Joe Anderson,
who  stepped down from  the Board at  the AGM, for 
their efforts and input over
their respective periods with the
About Algeta 
Algeta  is a company focused on developing novel targeted therapies
for patients
with   cancer  based  on  its  alpha-pharmaceutical 
platform.  The Company  is headquartered in Oslo, Norway, and has a
US subsidiary, Algeta US, LLC, based in Cambridge,  MA performing
commercial  marketing operations in  the US. Algeta is listed  on the
Oslo Stock Exchange (Ticker: ALGETA). For more information
Press release: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Algeta ASA via Thomson Reuters ONE 
For further information, please contact: 
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs 
Media enquiries:
Mark Swallow
Citigate Dewe Rogerson
+44 207 638 9571 
Knut Ekern
Gambit Hill & Knowlton
+47 22 04 82 00 
Kari Watson
MacDougall Biomedical Communications
+1 781 235 3060 
US investor enquiries:
Tricia Swanson
The Trout Group
+1 646 378 2953
Press spacebar to pause and continue. Press esc to stop.